SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-20-190493
Filing Date
2020-07-09
Accepted
2020-07-09 16:48:59
Documents
1
Group Members
BLACKSTONE CLARUS III L.L.C.BLACKSTONE GROUP INC.BLACKSTONE GROUP MANAGEMENT L.L.C.BLACKSTONE HOLDINGS I/II GP L.L.C.BLACKSTONE HOLDINGS II L.P.CLARUS VENTURES III GP, L.P.STEPHEN A. SCHWARZMAN

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO SCHEDULE 13D d945590dsc13da.htm SC 13D/A 156795
  Complete submission text file 0001193125-20-190493.txt   158661
Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences III, L.P. (Filed by) CIK: 0001597143 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1214
Type: SC 13D/A

Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Subject) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90651 | Film No.: 201020951
SIC: 2834 Pharmaceutical Preparations